He T, Xu B, Wang L, Wang Z, Shi H, Zhong C
Biomark Res. 2025; 13(1):10.
PMID: 39806475
PMC: 11730499.
DOI: 10.1186/s40364-024-00722-6.
Han Z, Qi L, Chen S, Zhang J, Guo X, Liang C
Biomark Med. 2025; 19(2):43-49.
PMID: 39781609
PMC: 11749384.
DOI: 10.1080/17520363.2024.2448112.
Zeng D, Zeng Q, Li S, Lu J, Cheng N
Sci Rep. 2025; 15(1):330.
PMID: 39747385
PMC: 11695853.
DOI: 10.1038/s41598-024-83324-4.
Wang H, Lai H, Su W, Kao J, Hsu W, Chen H
J Gastrointest Oncol. 2024; 15(5):2216-2229.
PMID: 39554567
PMC: 11565097.
DOI: 10.21037/jgo-24-351.
Padure A, Horhat R, Talpos-Niculescu I, Scheusan R, Anghel M, Rusu L
J Clin Med. 2024; 13(19).
PMID: 39407783
PMC: 11477337.
DOI: 10.3390/jcm13195723.
Neutrophil-Lymphocyte Ratio as a Predictor of Persistent Type 2 Endoleak after Endovascular Aneurysm Repair.
Kikuchi T, Kudo T, Yamamoto Y
Ann Vasc Dis. 2024; 17(3):255-263.
PMID: 39359559
PMC: 11444839.
DOI: 10.3400/avd.oa.24-00016.
Neutrophil-to-lymphocyte ratio as an index of treatment response to trans-arterial chemoembolization in hepatocellular carcinoma.
Shayegan N, Ayoobi N, Mohammadi E, Saberi H, Salahshour F, Alborzi F
Gastroenterol Hepatol Bed Bench. 2024; 17(3):253-259.
PMID: 39308535
PMC: 11413382.
DOI: 10.22037/ghfbb.v17i3.2925.
Association of healthy lifestyles with risk of all-cause and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease: results from the DFTJ cohort.
Deng Q, Zhang Y, Guan X, Wang C, Guo H
Ann Med. 2024; 56(1):2398724.
PMID: 39247937
PMC: 11385647.
DOI: 10.1080/07853890.2024.2398724.
The preoperative scoring system combining neutrophil/lymphocyte ratio and CA19-9 predicts the long-term prognosis of intrahepatic cholangiocarcinoma patients undergoing curative liver resection.
Bai S, Shi X, Dai Y, Wang H, Xia Y, Liu J
BMC Cancer. 2024; 24(1):1106.
PMID: 39237882
PMC: 11378368.
DOI: 10.1186/s12885-024-12819-0.
Effect of bile duct resection on the prognosis of patients with hepatocellular carcinoma combined with extrahepatic bile duct tumor thrombus.
Yu X, Liang Q, Wang J, Pei Y, Cai J, Chen L
BMC Cancer. 2024; 24(1):969.
PMID: 39112950
PMC: 11308446.
DOI: 10.1186/s12885-024-12717-5.
Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study.
Ohira M, Aoki G, Orihashi Y, Yoshimura K, Toshima T, Hatano E
BJS Open. 2024; 8(4).
PMID: 39092977
PMC: 11295212.
DOI: 10.1093/bjsopen/zrae079.
The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients.
Nakazawa N, Sohda M, Endo M, Hosoi N, Uchida S, Watanabe T
Cancer Chemother Pharmacol. 2024; 94(4):517-522.
PMID: 39060627
DOI: 10.1007/s00280-024-04692-2.
Biomarker of severity in hospitalised patients with COVID-19: a retrospective study.
Qian F, Liu Y, Cao Y, Huang J, Zhu R
BMJ Open. 2024; 14(7):e081627.
PMID: 39019644
PMC: 11256060.
DOI: 10.1136/bmjopen-2023-081627.
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.
Wang C, Yuan L, Wu X, Wang Y, Tian H, Zhang G
BMC Med. 2024; 22(1):252.
PMID: 38886794
PMC: 11184884.
DOI: 10.1186/s12916-024-03474-0.
A Multicenter International Retrospective Investigation Assessing the Prognostic Role of Inflammation-Based Scores (Neutrophil-to-Lymphocyte, Lymphocyte-to-Monocyte, and Platelet-to-Lymphocyte Ratios) in Patients with Intermediate-Stage....
Minici R, Venturini M, Guzzardi G, Fontana F, Coppola A, Piacentino F
Cancers (Basel). 2024; 16(9).
PMID: 38730572
PMC: 11083312.
DOI: 10.3390/cancers16091618.
Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
Jiang H, Li B, Wu M, Wang Q, Li Y
BMC Cancer. 2024; 24(1):428.
PMID: 38589844
PMC: 11000368.
DOI: 10.1186/s12885-024-12149-1.
Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk.
Liu K, Tang S, Liu C, Ma J, Cao X, Yang X
Front Immunol. 2024; 15:1337241.
PMID: 38481995
PMC: 10933001.
DOI: 10.3389/fimmu.2024.1337241.
Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization.
Ocal O, Kimm M, Hoang T, Pech M, Ocal E, Ben Khaled N
JHEP Rep. 2024; 6(4):100995.
PMID: 38440069
PMC: 10909776.
DOI: 10.1016/j.jhepr.2023.100995.
Advanced lung cancer inflammation index predicts overall survival of hepatocellular carcinoma after hepatectomy.
Wen Y, Liu G, Liao J, Xu J
Front Oncol. 2024; 14:1294253.
PMID: 38390261
PMC: 10882069.
DOI: 10.3389/fonc.2024.1294253.
Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors.
Guo Y, Wu W, Sun B, Guo T, Si K, Zheng C
Front Oncol. 2024; 14:1293680.
PMID: 38322419
PMC: 10844468.
DOI: 10.3389/fonc.2024.1293680.